Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle invasive bladder cancer (NMIBC).
Pfizer Aims To Have First PD-1 Inhibitor Approved In Early NMIBC Setting
The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.
More from Immuno-oncology
More from Scrip
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.